TY - JOUR
T1 - Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin
AU - Takahashi, Tsunehiro
AU - Akashi-Tanaka, Sadako
AU - Fukutomi, Takashi
AU - Watanabe, Toru
AU - Katsumata, Noriyuki
AU - Miyakawa, Kunihisa
AU - Hasegawa, Tadashi
AU - Tsuda, Hitoshi
PY - 2001/8
Y1 - 2001/8
N2 - Seventy-eight patients with primary breast cancer over 3 cm in diameter in stages IIA, IIB, IIIA and III B according to the UICC classification received neoadjuvant chemotherapy from August 1, 1998 to June 30, 2000 at the Breast Division of the National Cancer Center Hospital. Neoadjuvant chemotherapy consisted of doxorubicin (Adriamycin: ADM) 50 mg/m 2 and docetaxel (Taxotere: DOC) 60 mg/m 2 every three weeks. The overall clinical response to this regimen was 88% (69/78). Although neoadjuvant chemotherapy with this regimen achieved good responses in patients with breast cancer, 2 patients presented with progressive disease (PD) after treatment. One patient had inflammatory breast cancer (IBC) and the other had primary squamous cell carcinoma (SCC) of the breast. There were 4 cases of IBC and one case of SCC of the breast who received neoadjuvant chemotherapy in this series. Our observations suggest that this regimen might not be effective for these types of breast cancer.
AB - Seventy-eight patients with primary breast cancer over 3 cm in diameter in stages IIA, IIB, IIIA and III B according to the UICC classification received neoadjuvant chemotherapy from August 1, 1998 to June 30, 2000 at the Breast Division of the National Cancer Center Hospital. Neoadjuvant chemotherapy consisted of doxorubicin (Adriamycin: ADM) 50 mg/m 2 and docetaxel (Taxotere: DOC) 60 mg/m 2 every three weeks. The overall clinical response to this regimen was 88% (69/78). Although neoadjuvant chemotherapy with this regimen achieved good responses in patients with breast cancer, 2 patients presented with progressive disease (PD) after treatment. One patient had inflammatory breast cancer (IBC) and the other had primary squamous cell carcinoma (SCC) of the breast. There were 4 cases of IBC and one case of SCC of the breast who received neoadjuvant chemotherapy in this series. Our observations suggest that this regimen might not be effective for these types of breast cancer.
KW - Breast cancer
KW - Inflammatory breast cancer
KW - Neoadjuvant chemotherapy
KW - Progressive disease
KW - Squamous cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=0035233737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035233737&partnerID=8YFLogxK
U2 - 10.1007/BF02967514
DO - 10.1007/BF02967514
M3 - Article
C2 - 11668246
AN - SCOPUS:0035233737
VL - 8
SP - 234
EP - 237
JO - Breast Cancer
JF - Breast Cancer
SN - 1340-6868
IS - 3
ER -